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Abstract
Introduction High plasma triacylglyceride levels are known to be associated with increased risk of atherosclerotic cardio-
vascular disease. Apolipoprotein C-III (apoC-III) is a key regulator of plasma triacylglyceride levels and is associated with 
hypertriglyceridemia via a number of pathways. There is consistent evidence for an association of cardiovascular events with 
blood apoC-III level, with support from human genetic studies of APOC3 variants. As such, apoC-III has been recognised 
as a potential therapeutic target for patients with severe hypertriglyceridaemia with one of the most promising apoC-III-
targeting drugs, volanesorsen, having recently progressed through Phase III trials.
Objectives To exploit a rare loss of function variant in APOC3 (rs138326449) to characterise the potential long-term treat-
ment effects of apoC-III targeting interventions on the metabolome.
Methods In a recall-by-genotype study, 115 plasma samples were analysed by UHPLC-MS to acquire non-targeted metabo-
lomics data. The study included samples from 57 adolescents and 33 adults. Overall, 12 985 metabolic features were tested 
for an association with APOC3 genotype.
Results 161 uniquely annotated metabolites were found to be associated with rs138326449(APOC3). The highest proportion 
of associated metabolites belonged to the acyl-acyl glycerophospholipid and triacylglyceride metabolite classes. In addition 
to the anticipated (on-target) reduction of metabolites in the triacylglyceride and related classes, carriers of the rare variant 
exhibited previously unreported increases in levels of a number of metabolites from the acyl-alkyl glycerophospholipid class.
Conclusion Overall, our results suggest that therapies targeting apoC-III may potentially achieve a broad shift in lipid profile 
that favours better metabolic health.
Keywords APOC3 · Triglyceride-rich lipoprotein · Genotype · Metabolites · ALSPAC · Recall-by-genotype
1 Introduction
The relationship between plasma triacylglyceride (TAG) 
levels and cardiovascular disease (CVD) has been the focus 
of much research over the past four decades (Nordestgaard Electronic supplementary material The online version of this article (https ://doi.org/10.1007/s1130 6-020-01689 -9) contains 
supplementary material, which is available to authorized users.
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2016). In that time, a series of population-based cohort stud-
ies including several meta-analyses have demonstrated that 
high plasma TAG levels are associated with increased risk 
of atherosclerotic CVD (Hokanson and Austin 1996; Sar-
war et al. 2007). Alterations in dynamics of triglyceride-
rich lipoproteins (TRLs) (i.e. very low-density lipoprotein 
(VLDL) and chylomicrons), including over-production and/
or delayed clearance of VLDL, can lead to high levels of 
TAGs (hypertriglyceridemia) (Chan et al. 2008). The role of 
apolipoprotein C-III (apoC-III) in regulating the metabolism 
of TRLs has been well characterised (Ramms and Gordts 
2018). apoC-III is a glycoprotein secreted predominantly 
by the liver but also by the intestine and is a major com-
ponent of TRLs but also, to a lesser extent, detectable in 
high-density lipoproteins (HDL) and low-density lipoprotein 
(LDL) (Olkkonen et al. 2018). apoC-III is associated with 
hypertriglyceridemia via a number of pathways, including 
its action as an inhibitor of lipoprotein lipase (LPL) (the 
enzyme that metabolises TAGs from TRL to fatty acids and 
enables their clearance from the circulation) (Chan et al. 
2008; Ioanna Gouni-Berthold 2017). There is consistent evi-
dence for an association of cardiovascular events with blood 
apoC-III level in total plasma or in VLDL and LDL (van 
Capelleveen et al. 2018; Wyler von Ballmoos et al. 2015) 
with a suggestion that the pro-atherosclerotic properties of 
the protein extend beyond its role in increasing TAG levels 
(Ioanna Gouni-Berthold 2017), including evidence that sup-
ports a direct effect of apoC-III on vascular and inflamma-
tory functions (Chan et al. 2008; Kanter et al. 2019; Toth 
2016).
Studies in humans have reinforced the potential impor-
tance of apoC-III to lipoprotein regulation and CVD risk. 
The APOC3 gene sits in a gene cluster with APOA1, APOA4 
and APOA5 on Chromosome 11. Initially, work was lim-
ited to the identification and characterisation of structural 
variants of APOC3 present in individuals or small families 
(reviewed in (van Dijk et al. 2004)). The functional conse-
quences of this variation appears to include effects on lipo-
protein metabolism (Liu et al. 2000; von Eckardstein et al. 
1991) and insulin responsiveness (Waterworth et al. 2003). 
More recently, genome-wide association studies (GWAS) 
conducted on large numbers of individuals have found both 
common and rare variants in and around this set of genes to 
be associated with a range of lipid traits (Pollin et al. 2008; 
Tachmazidou et al. 2013; Willer et al. 2013). Subsequently, 
a series of large sequencing efforts, both genome-wide (TG 
and HDL Working Group of the Exome Sequencing Pro-
ject, National Heart, Lung, and Blood Institute et al. 2014; 
Timpson et al. 2014) and candidate gene driven (Jørgensen 
et al. 2014), have contributed a further three apparently car-
dioprotective APOC3 variants, including the rare loss of 
function variant, rs138326449. As well as being informa-
tive with respect to apoC-III function in their own right, 
these studies have delivered a set of genetic variants that can 
be used in the context of applied genetic epidemiology. For 
example, stratifying individuals based on APOC3 genotypes, 
rather than plasma TAG levels, enables circumvention of 
confounding factors that affect both plasma TAG levels and 
CVD, and modelling of life course effects in an approach 
referred to as Mendelian randomization (MR) (Cohen et al. 
2014; Davey Smith and Hemani 2014; Jørgensen et al. 2014; 
TG and HDL Working Group of the Exome Sequencing Pro-
ject, National Heart, Lung, and Blood Institute et al. 2014).
Due to its key role in regulating levels of circulating TRLs 
and supporting genetic evidence, apoC-III has been identi-
fied as a potential therapeutic target for patients with severe 
hypertriglyceridaemia (Olkkonen et al. 2018). Volanesorsen 
(formerly ISIS 304801) is a second-generation antisense oli-
gonucleotide against APOC3 mRNA which inhibits apoC-
III synthesis and has recently been through Phase III trials 
(Gaudet et al. 2017; Ionna Gouni-Berthold et al. 2018). Also 
in the development stage is a monoclonal antibody designed 
to target lipoprotein bound human apoC-III which mimics 
the action of a missense variant in APOC3 (A43T) (Khetar-
pal et al. 2017). These short-term studies (up to 52 weeks in 
the case of volanesorsen) appear to show efficacy of apoC-
III targeting drugs but critically have not been able to evalu-
ate either the efficacy or safety of targeting apoC-III in the 
longer term. Therefore, an opportunity exists to provide a 
detailed characterisation of the long-term effects of apoC-III 
inhibition for the treatment of hypertriglyceridaemia.
By using recall by genotype (Corbin et  al. 2018), a 
population-based approach derived theoretically from MR, 
we can offer evidence to strengthen inference from exist-
ing observational studies and randomized controlled trials 
(RCTs). Functional (or functional-linked) genetic variants 
within APOC3 can act as proxies for treatment, mimicking 
the effect of exposure to apoC-III-targeting drugs in a setting 
analogous to an RCT but, reflecting much longer term (life-
time) exposure. Previously, using a high throughput nuclear 
magnetic resonance metabolomics platform to quantify over 
200 metabolic measures in more than 13,000 individuals, 
we identified associations between rs138326449(APOC3) 
and VLDL and HDL composition, other cholesterol meas-
ures, and fatty acids (Drenos et al. 2016). In the comple-
mentary study reported here, we use a recall-by-genotype 
study design to further probe the downstream consequences 
of carrying the rare allele at rs138326449(APOC3) and in 
doing so, model the apoC-III-targeting drug response. Using 
an untargeted ultra high performance liquid chromatogra-
phy-mass spectrometry (UHPLC-MS) approach to look at 
and beyond the lipidome to the wider metabolome (Dunn 
et al. 2011, 2015) we aim to both confirm the likely on-target 
(intended) treatment effects (i.e. lowering of circulating indi-
vidual TAGs) but also explore the potential for previously 
unobserved (off-target) metabolic consequences (that may 
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be linked to positive or negative health outcomes or side 
effects) of apoC-III targeting interventions.
2  Materials and methods
2.1  Study population
The Avon Longitudinal Study of Parents and Children 
(ALSPAC) is a population-based, prospective birth cohort 
(Boyd et al. 2013; Fraser et al. 2013). ALSPAC recruited 
14,541 pregnant women who were resident in Avon, UK 
and had expected dates of delivery 1st April 1991 to 31st 
December 1992. Since then, the health and development of 
mothers and their children has been followed across the life-
course. Further details of the cohort are available in Supple-
mentary Methods (ESM_1) and the study website contains 
details of all the data that is available through a fully search-
able data dictionary and variable search tool (https ://www.
brist ol.ac.uk/alspa c/resea rcher s/our-data/). Ethical approval 
for this study was obtained from the ALSPAC Ethics and 
Law Committee and the Local Research Ethics Commit-
tees. Details of the ethics approvals relevant to the ALSPAC 
cohort in general can be found on the study website (https ://
www.brist ol.ac.uk/alspa c/resea rcher s/resea rch-ethic s/) and 
approvals relevant to this study specifically can be found in 
Supplementary Methods (ESM_1). Participants have pro-
vided informed consent for use of their samples and data.
2.2  Experimental design
2.2.1  Sample collection
In this study, we used pre-existing plasma samples collected 
during routine follow-up clinics. During clinic appoint-
ments, blood was drawn into lithium heparin tubes which 
were centrifuged at 2260 g for 10 min at 4–5 °C. Heparin 
plasma was then aliquoted out and stored at − 80 °C. Plasma 
samples were frozen within 120 min of collection.
2.2.2  Sample selection
A recall-by-genotype study design was used to select a sub-
set of stored samples for analysis. Previously, genotyping 
for the rs138326449 splice variant APOC3 mutation was 
performed for all ALSPAC participants (mothers and off-
spring – referred to herein as ‘young participants’) who had 
a suitable DNA sample using KASPAR at KBioscience 
(www.lgcge nomic s.com) (Drenos et al. 2016). A list of 
carriers of the minor ‘A’ allele at rs138326449 was gener-
ated and cross-checked against a list of stored samples for 
these same participants. Where a sample was available for 
a carrier, samples from two age and sex-matched ‘controls’ 
(i.e. homozygotes for the major ‘G’ allele) attending the 
same clinic were identified for inclusion. Where additional 
samples (from other time points) were available for carri-
ers, these were also selected to be analysed, giving repeated 
measurements for a subset of participants. In all clinics, par-
ticipants who were assessed in the morning were instructed 
to fast overnight and those that attended after 2 pm were 
instructed to fast for at least six hours prior to their appoint-
ment. However, there were nine samples within the mother’s 
dataset which had to be considered non-fasting since the 
participant had reported consuming food and/or drink within 
six hours of blood sampling.
2.3  Ultra high performance liquid 
chromatography‑mass spectrometry 
(UHPLC‑MS)
Plasma samples were extracted applying organic solvents 
and analysed applying two complementary UHPLC-MS 
assays applied to study water-soluble metabolites (HILIC 
assay) and lipid metabolites  (C18 reversed phase assay). All 
samples were randomised in their sample preparation and 
analysis order. A single pooled QC sample was prepared 
from all biological samples and was applied to quantify and 
report data quality. Four different datasets were acquired: 
HILIC positive ion mode (HILIC-POS), HILIC negative 
ion mode (HILIC-NEG), lipids positive ion mode (LIPIDS-
POS) and lipids negative ion mode (LIPIDS-NEG). Raw 
data processing was performed using XCMS (Smith et al. 
2006). Full details of sample preparation, UHPLC-MS anal-
ysis and raw data processing can be found in Supplementary 
Methods (ESM_1).
An overview of quality control (QC) and data filtering 
procedures is shown in Fig. 1 and full details provided in 
Supplementary Methods (ESM_1). In brief, metabolite fea-
tures with a relative standard deviation (RSD) > 30% and a 
percentage detection rate < 70% in pooled QC samples were 
deleted from the dataset.
To increase the quality of the data, filters were applied 
to the study samples (i.e. excluding pooled QC samples) 
and features within each of the four UHPLC-MS datasets. 
Samples with > 50% missing data and/or a total peak area 
(TPA) greater than three standard deviations above the mean 
TPA were excluded. After sample exclusion, within-class 
(carrier vs. control) feature missingness was calculated. 
Features were excluded from all subsequent analyses if 
they had > 30% missing data in both classes. Data was then 
normalised by probabilistic quotient normalisation (PQN) 
(Frank Dieterle et al. 2006) and rank normal transformed 
(Aulchenko et al. 2007) prior to statistical analysis.
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2.4  Existing lipid measures
In addition to the UHPLC-MS derived metabolic measures, 
we had available a set of (pre-existing) basic lipid meas-
ures assessed by standard laboratory assays (high-density 
lipoprotein (HDL), low-density lipoprotein (LDL) and total 
triacylglycerides (TAG)) for a subset of the same individuals 
and time points. Further details of the measurement of these 
basic lipid measures can be found in Supplementary Meth-
ods (ESM_1). These basic lipid measures were analysed 
alongside the UHPLC-MS dataset for comparative purposes 
although the measures themselves are not directly compara-
ble. No transformation was applied to the basic lipid meas-
ures prior to analysis.
Fig. 1  An overview of the 
data processing pipeline. PQN 
probabilistic quotient normali-
zation, QC quality control, RSD 
relative standard deviation, SD 
standard deviations. Dashed 
lines indicate the flow for sensi-
tivity analyses
Raw data
115 samples
24,604 features
Filtered data
Min. 112 samples
12,985 features
Sample filter:
Exclude if: missingness > 50%, or,
total peak area > ± 3SD from the mean
Feature filter:
Exclude if: missingness > 30% in both genotype groups
Missing value 
imputaon by 
random forest Normalizaon by PQN
Rank transformaon to normality
Dataset for
parametric analyses
Min. 112 samples
12,985 features
Data used for calculang fold 
change (aer removal of non-
fasng samples) 
Exclusion of non-fasng samples (n=9)
Dataset for
primary analyses
Min. 103 samples
12,985 features
Data used for sensivity analysis 
including non-fasng samples
Post QC data
115 samples
14,407 features
Feature QC (based on QC samples):
Exclude if: RSD > 30% and/or detecon rate < 70% 
Imputed version of 
data used to generate 
PCA scores plots as 
part of QC (Figure S1)
Data used for assessing 
differenal missingness (aer 
removal of non-fasng samples) 
Idenficaon of the subset 
of associated features
Lists of idenfied metabolites 
from the 4 UHPLC-MS datasets 
combined and reduced to a set of 
unique associated metabolites
Stascal analysis
Stascal analysis
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2.5  Statistical analysis
All statistical analyses described were conducted in R v3.5 
or later (R Core Team 2019).
2.5.1  Primary analysis
For the primary analysis, we only included sam-
ples that could be considered fasting (see above). We 
tested for an association between the metabolic features 
(UPLC-MS-derived and existing lipid measures) and 
rs138326449(APOC3) in three datasets: young participants 
only (n = 21 carriers/42 non-carriers with a mean age of 
16 years), mothers only (n = 21 carriers/22 non-carriers, 
with a mean age of 49 years) and the combined dataset 
(young participants and mothers) (n = 42 carriers/64 non-
carriers). Only samples and features that passed the above 
QC and filtering steps were analysed. We used either a sim-
ple linear model or a mixed linear regression model fitted by 
maximum likelihood (depending on the number of repeated 
measures) and including age and sex as fixed effects to test 
the association between each feature (the dependent vari-
able) and rs138326449(APOC3) (for further details see Sup-
plementary Methods (ESM_1)). Features with a Benjamini 
and Hochberg (BH)-adjusted false discovery rate (FDR) 
p-value (Benjamini and Hochberg 1995) of < 0.05 in at least 
one of the three primary analyses (combined, mothers only, 
young participants only) were considered to be associated 
with rs138326449(APOC3) genotype. For these associated 
features, the fold change was also calculated as the ratio 
between the two group means (carrier group mean/non-
carrier group mean), using data before rank-transformation 
was applied. In order to evaluate the variance in metabolite 
levels explained by the fixed effects (age, sex and genotype), 
a simple linear model was fitted across all features (making 
no adjustment for repeated measures or relationships).
Missing values can occur in the data for a number of 
reasons both technical and biological. One of the main rea-
sons for missing data is that the feature in question is not 
present in the sample or is only present at very low levels 
(i.e. its concentration is below the level of detection). In 
this situation, the linear modelling approach described above 
would be unable to detect associations between the predictor, 
rs138326449(APOC3) genotype, and presence or absence of 
the feature. Therefore, a Fisher’s exact test was performed 
to identify features for which there was a difference in the 
proportion of missingness between carriers and non-carri-
ers. For this analysis we used the combined dataset (young 
participants and mothers) (n = 42 carriers/64 non-carriers). 
Features with a BH-adjusted p-value of p < 0.05 were con-
sidered to be differentially missing in carriers compared to 
non-carriers.
2.5.2  Sensitivity analyses
Two sensitivity analyses were performed (see Supplemen-
tary Methods (ESM_1) for more details). In the first, unlike 
in the primary analysis, non-fasting samples were retained 
in the analysis and in the second, an imputed version of the 
metabolite dataset was analysed.
2.6  Feature identification
We sought to structurally identify all features identified as 
being associated with rs138326449(APOC3) genotype in 
any one of either the primary or sensitivity analyses. These 
metabolites were identified applying accurate MS data (and 
MS/MS fragmentation data, where available) to a confidence 
level 2 as defined by the Metabolomics Standards Initiative 
(Sumner et al. 2007). For full details of the identification 
procedure, see Supplementary Methods (ESM_1). Where 
multiple features were annotated as the same metabolite 
(either within or across UHPLC-MS datasets), results for 
only one feature, that with the strongest association (small-
est p-value) with rs138326449(APOC3) genotype, were 
retained. The search for duplicate metabolites was carried 
out within each of the three datasets (combined, mothers 
only, young participants only). Results are reported and fig-
ures plotted for this set of uniquely annotated features. All 
lipids are reported according to shorthand notation as has 
been reported previously (Liebisch et al. 2013).
3  Results
The dataset consisted of samples from 57 young participants 
(‘offspring’) (15 carriers/42 controls) and 33 mothers (11 
carriers/ 22 controls), with repeat samples analysed for a 
subset of carriers (subject to sample availability). In total, 
115 samples (51 from carriers and 64 from controls) were 
analysed by UHPLC-MS. Characteristics of the samples can 
be found in Table 1; results from a two-sample Wilcoxon 
rank sum test (Bauer 1972; Hollander and Wolfe 1999) 
suggested there was no difference in age or BMI between 
groups, but provided strong evidence for an effect of car-
rier status on HDL and TAG. There was little evidence 
for a difference between groups with respect to potential 
confounders or general indicators of health (Table S1). In 
total, 12,985 features derived from four UHPLC-MS runs 
were tested for association with genotype group (for more 
details see Table S2). Multiple features were detected for 
each metabolite because of the complexity of ion formation 
in the electrospray ionisation process and a metabolite can 
be detected in more than one assay. We estimate the number 
of metabolites detected to be in the range of 1000–2000 
metabolites. After the exclusion of nine non-fasting samples 
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from the mother’s sample set (all from rare variant carriers) 
for quality control in primary analyses, the number of sam-
ples ranged from 103 to 105 (see Fig. 1 for an overview of 
the data processing pipeline).
3.1  Over 300 features were identified as associated 
with rs138326449(APOC3)
A total of 311 (2.4%) features showed evidence of asso-
ciation with rs138326449(APOC3) in the primary analysis 
(counting unique features across the three analyses—young 
participants only, mothers only, and young participants and 
mothers combined) (Table S3). The highest number of asso-
ciations was observed in the combined (mothers and young 
participants) analysis (287), followed by the young partici-
pants only analysis (195), with relatively few observed in the 
mothers only analysis (19). The majority (78.1%) of associa-
tions came from features identified in the lipids positive ion 
mode (LIPIDS-POS) with relatively few associations com-
ing from the other assays (2.6% from LIPIDS-NEG, 19.0% 
from HILIC-POS, 0.3% from HILIC-NEG). Most features 
found to be associated in the mothers and/or the young par-
ticipant’s datasets were also associated in the combined data-
set (189 out of 213) (Fig. S1A).
The majority (236 of 287) of the associations seen in 
the primary analysis (of the combined dataset) replicated in 
both sensitivity analyses (Fig. S1B). Including non-fasting 
samples in the analysis resulted in fewer associations whilst 
using an imputed version of the data increased the number 
of associated features. Of the basic lipid measures, HDL and 
TAG were also associated with rs138326449(APOC3) in the 
primary analysis (in all three datasets). Using the simple 
linear model (including young participants and mothers) we 
estimated a per ‘A’ allele effect on HDL of 0.51 mmol/l (SE: 
0.08, p = 6.85 × 10−09) and on total TAG of − 0.40 mmol/l 
(SE: 0.09, p = 2.02 × 10−05).
For the subset of all associated features (n = 311), the 
percentage variance in standardized individual metabo-
lite levels explained by genotype group ranged from 0.4 to 
36.7% (median: 16.2%) as compared to 36.6% in the case of 
HDL and 23.4% for TAG. This compares to a range of 0.0 
to 36.0% (median: 2.1%) explained by age (in years) and 0.0 
to 26.9% (median: 0.6%) explained by sex, across all tested 
features. Estimates of fold change in individual metabolite 
levels observed in carriers of the rare derived ‘A’ allele rela-
tive to controls for the subset of associated features ranged 
from 0.33 to 1.61 compared to 1.37 for HDL and 0.55 for 
TAG.
In addition, 53 features were found to have a different 
degree of missingness in carriers as compared with non-
carriers (in the combined dataset). The majority came from 
the HILIC-POS class (71.7%) with the relatively fewer from 
the LIPIDS-POS (22.6%), LIPIDS-NEG (3.8%) and HILIC-
NEG (1.9%) sets. The vast majority (51/53) had greater lev-
els of missingness in the carrier group than in the non-car-
rier group, indicating that they occurred at detectable levels 
less often in the carrier group. Forty-eight of the 53 features 
identified were not in the list of 311 associated features from 
the primary (linear model-based) analyses. Therefore, a total 
of 359 features appear to be influenced by the presence of 
the rare derived ‘A’ allele at rs138326449.
Table 1  Sample characteristics
a Non-fasting samples were excluded from the primary analysis
b Calculated across all samples (rather than unique individuals)
c Using all available data (n = 39 young participants; n = 32 mothers); HDL high-density lipoprotein, LDL low-density lipoprotein, TAG triacyl-
glycerides. A two-sample Wilcoxon rank sum test (Bauer 1972; Hollander and Wolfe 1999) was performed in R v3.6.1 (R Core Team 2019) to 
test for a difference in quantitative traits between carriers and non-carriers: n = p > 0.05, *p < 0.05, **p < 0.01, ***p < 0.001
Young participants Mothers
Carriers Non-carriers Carriers Non-carriers
No. of samples (carriers/non-carriers) 21 42 30 22
No. of fasted samples (carriers/non-carriers)a 21 42 21 22
No. of unique individuals (carriers/non-carriers) 15 42 11 22
Sex (% females)b 47.6% 47.6% 100% 100%
Age (years) at sampling (mean, standard deviation)b 16.2 (1.2) 16.2 (1.2)n 49.6 (6.0) 47.2 (5.1)n
Body mass index (mean, standard deviation)b 21.6 (3.2) 22.3 (4.3)n 24.8 (3.7) 25.4 (4.5)n
HDL mmol/L (mean, standard deviation)c 1.62 (0.30) 1.19 (0.25)*** 1.93 (0.49) 1.42 (0.25)**
LDL mmol/L (mean, standard deviation)c 2.12 (0.45) 1.89 (0.63)n 2.56 (0.43) 3.16 (0.80)*
TAG mmol/L (mean, standard deviation)c 0.45 (0.06) 0.81 (0.39)*** 0.59 (0.14) 1.03 (0.40)**
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3.2  Associations were seen predominantly 
in glycerophospholipids and triacylglycerides
Of the 311 features associated with rs138326449(APOC3) 
in the linear models, 183 could be identified, representing 
161 unique metabolites across the three datasets (153 in 
the combined analysis, 104 in young participants only and 
12 in mothers only) (Table S3 and Fig. S2A). Overall, the 
highest proportion of associated metabolites belong to the 
acyl-acyl glycerophospholipid (GPL) and TAG metabolite 
classes (Table 2 and for the full list Table S4). Box and 
whisker plots showing the distribution of the 183 identi-
fied metabolites in carriers versus controls based on nor-
malised data (before rank transformation) in the combined 
dataset can be found in Fig. S3. 130 unique identified 
metabolites were found to be common across the primary 
analysis and the two sensitivity analyses (Fig. S2B). Of 
the 53 features found to be differentially missing between 
carriers and non-carriers, 16 were identified (Table S5).
3.3  A metabolic signature of rs138326449(APOC3) 
carrier status was evident
Visualisation of the 153 (identified) unique associated 
metabolites from the combined analysis in a heatmap with 
samples and metabolites clustered using Ward’s hierarchi-
cal clustering method (Murtagh and Legendre 2014; Ward 
1963) as in Fig. 2, suggests broad separation of the samples 
into three groups—two non-carrier dominated subsets and 
one carrier dominated subset. Removing metabolites in the 
TAG class (i.e. those considered to be the primary target of 
apoC-III lowering therapies) in an exploratory analysis led 
to improved separation between carriers of the rare allele at 
rs138326449(APOC3) and non-carriers (Fig. S4). Within 
metabolite classes, the majority of associated metabolites 
within a class tend to move in the same direction (Fig. S5) 
with a small number of exceptions that in some cases may 
relate to molecule size, as proxied by mass to charge ratio 
(m/z) (Fig. 3). Further, within the GPL classes, we observe 
high correlations between UHPLC-MS-derived measures 
and those from traditional measures of metabolic health 
(HDL, LDL, TG) (Fig.’s S6A and S6B).
4  Discussion
By exploiting the properties of genetic variation at the level 
of the population we have provided a comprehensive evalu-
ation of the metabolic consequences of carrying the rare 
allele at rs138326449(APOC3) with a view to informing the 
therapeutic potential of apoC-III targeting drugs. This work 
demonstrates how a recall-by-genotype study design can 
be advantageous given the appropriate conditions—in this 
case, a relatively rare functional variant (minor allele fre-
quency ~ 0.25% (UK)) in a gene of therapeutic relevance (i.e. 
a drug target) and a cohort with the necessary genetic data, 
stored samples and permissions in place to undertake such 
studies. This work complements existing literature reporting 
the outcomes of clinical trials of novel apoC-III targeting 
therapeutic agents, notably, volanesorsen.
A series of Phase I to III trials of this drug and a related 
drug, AKCEA-APOCIII-LRX, have shown decreases of both 
apoC-III production and TAG concentrations in preclinical 
models and healthy volunteers (Graham et al. 2013) and in 
patients with familial chylomicronemia syndrome (FCS) 
(Gaudet et al. 2014, 2017) and those with hypertriglyceri-
daemia (Alexander et al. 2019; Gaudet et al. 2015; Ionna 
Gouni-Berthold et al. 2018). Whilst conclusions from the 
Phase III trials were that the therapy was generally well-
tolerated (indeed, volanesorsen was recently approved in 
Europe for treatment of FCS (Macchi et al. 2019)), there are 
two important limitations to these trials in terms of under-
standing the full effects of such an intervention. Firstly, these 
trials have not been able to evaluate either the efficacy or 
safety of targeting apoC-III in the longer term. Long term 
effects are of particular concern since this kind of drug has 
the potential to be used chronically following diagnosis 
with hypertriglyceridemia. Secondly, whilst results from 
genetic epidemiology suggest the reduction in CVD risk 
associated with the down-regulation of apoC-III is unlikely 
to be entirely due to lowering of TRLs, trials to date have 
measured a relatively small number of outcomes focusing 
on standard lipoprotein profiles and are therefore not well 
placed to interrogate alternative pathways. Results here go 
some way towards addressing this gap in knowledge. The use 
of samples from both adolescents and adults provide some 
confidence in terms of the generalisability of our findings 
and adds further value to this work as a comparator to results 
Table 2  The distribution across (selected) metabolite classes of iden-
tified metabolites from the primary analysis (for full table see Sup-
plementary Table S4)
GPL Glycerophospholipid
Metabolite class No. of associated features (% of total)
Combined Young participants Mothers
Acyl-acyl GPL 46 (30%) 39 (38%) 1 (8%)
Triacylglyceride 34 (22%) 5 (5%) 9 (75%)
Acyl-alkyl GPL 24 (16%) 18 (17%) 0
Diacylglyceride 18 (12%) 14 (13%) 0
Cardiolipin 11 (7%) 11 (11%) 0
Ceramide 7 (5%) 7 (7%) 0
Fatty acid and fatty ester 5 (3%) 4 (4%) 0
Total 153 104 12
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of RCTs which are generally restricted in terms of the target 
population and chronic effects of treatment.
We observed a clear metabolic signature associated with 
carrying the minor allele at rs138326449(APOC3). The list 
of associated metabolites was dominated by metabolites 
from the GPL (both acyl-acyl and acyl-alkyl) and TAG 
classes but also included other lipid classes (diacylglycer-
ides, ceramides, fatty acid and fatty esters). A detailed sum-
mary of our findings, including insight into their potential 
relevance to health and disease can be found in Table S6 
in Supplementary Materials (ESM_1). Overall, our results 
point to a broad shift in lipid profile that appears to favour 
better metabolic health in those carrying the minor allele at 
rs138326449(APOC3). We observed not only the anticipated 
(on-target) reduction of many metabolites in the TAG and 
acyl-acyl GPL classes in carriers of the rare variant, but 
also previously unreported increases in levels of a number 
of other metabolites. Given the current data, it is not pos-
sible to evaluate the extent to which each change we see 
represents a direct effect of the functional change induced by 
the mutation (‘horizontal pleiotropy’) versus a downstream 
consequence of that effect (‘vertical pleiotropy’) although 
it is likely that both of these mechanisms contribute to the 
profile effects we observe.
The class with the highest proportion of metabolites 
showing increased concentrations was the acyl-alkyl GPL 
Acyl.carnitine.metabolism
Cardiolipin
Ceramide
Diacylglyceride
Energy metabolism
Fatty acid and fatty ester
GPL (acyl−acyl)
GPL (acyl−alkyl)
Gut microbial
Lysoglycerophospholipid
Other
Sphingolipid
Triacylglycerides
Ubiquinone−2
VitD metabolism
M
.C
la
ss
G.group
Fig. 2  Heatmap showing the 153 unique associated metabolites 
based on data from the combined dataset residualised on age and 
sex. M.Class metabolite class (see plot for colour key), GPL glycer-
ophospholipid, G.group = genotype group (red = young participants, 
non-carriers; dark red = mothers, non-carriers; green = young partici-
pants, carriers of the ‘A’ allele; dark green = mothers, carriers of the 
‘A’ allele (colour figure online)
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class. A number of metabolites in this class have previously 
been associated with positive health effects (see Table S6 
for details). In addition, a small number of metabolites in 
the TAG class showed increased concentrations in rare vari-
ant carriers. These three TAGs were amongst the largest 
TAG molecules identified (as determined by molecular mass 
(m/z)) and had relatively high levels of fatty acid unsatura-
tion (i.e. more fatty acid double bonds). This is interesting 
in the context of evidence that a distinct pattern exists within 
TAG subspecies such that the number of carbon atoms and 
double bonds appear to be relevant with respect to CVD 
risk (Ho et al. 2016; Rhee et al. 2011; Stegemann et al. 
2014; Toledo et al. 2017). Overall, the increase in poten-
tially favourable metabolites may go some way to explaining 
the previously observed discordance between the size of the 
cardioprotective effect of APOC3 and its impact on LDL-
cholesterol levels alone (Cohen et al. 2014).
Fig. 3  Effect sizes by metabolite class. Effect estimates (betas) taken 
from linear mixed model with age, sex and pedigree fitted, and using 
the combined dataset after rank-normal transformation. The same 
plot ordered by effect estimates (beta) (instead of mass to charge ratio 
(m/z)) can be found in Fig. S5 (colour figure online)
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As well as the broad metabolic signature associated with 
carrying the minor allele at rs138326449(APOC3), there 
are inter-individual differences in metabolic profile. The 
hierarchical clustering algorithm appeared to differentiate 
two sub-groups within the non-carrier class, one contain-
ing individuals with much higher levels of TAGs and other 
potentially detrimental molecules than the carrier group and 
one in which only moderately higher levels were observed. 
The latter group was more similar to the carrier group over-
all and included 11 carrier samples (8 from mothers and 3 
from young participants). Factors that could be contributing 
to the variation in metabolite levels that we see could include 
other genetic variants and lifestyle differences. Whilst the 
study was not sufficiently well-powered to enable meaning-
ful comparisons to be made across the two age groups with 
respect to the associated metabolites, we see a weak corre-
lation between p-value based ranks derived in the mother’s 
dataset as compared to the young participants (r = 0.24). 
When combined with the fact that fewer features were asso-
ciated with carrier status in the mothers as compared to the 
young participants, one might hypothesise that the effect of 
the variant is attenuated or at least modified with age, via 
interaction with environmental variables.
The work presented here is subject to limitations. Due 
to the low minor allele frequency at rs138326449(APOC3), 
even including all available samples from carriers gave a 
relatively small total sample size. Therefore, confirmation of 
our results in other collections would be beneficial. Further 
limitations relate mainly to the interpretation of our find-
ings rather than the study procedures themselves. We have 
discussed the possible implications of our findings in the 
context of apoC-III as a therapeutic target, but genetic mod-
els such as this are not a perfect proxy for pharmacologic 
therapy—any effects on non-apoC-III-related pathways can-
not be assessed in this single-gene framework. Furthermore, 
due to the correlation (linkage disequilibrium) between 
genetic variants located close together in the genome, 
the effects we observe may not be entirely attributable to 
rs138326449(APOC3).
In conclusion, we made use of existing samples from an 
established biobank in a recall-by-genotype framework in 
order to maximise study power for a given number of sam-
ples analysed. The untargeted UHPLC-MS approach used 
returned results for a large number of metabolic features 
allowing a more comprehensive evaluation of the impact 
of rs138326449(APOC3) genotype on the global metabolic 
network of water-soluble and lipid metabolites than has pre-
viously been described. Studied in this way, genetic variation 
represents lifetime exposure to the effects of mutation, which 
in this case mirrors the action of apoC-III-targeting drugs. 
Our results suggest therapeutic targeting of apoC-III may 
result in a positive health effect both through the reduction 
of harmful lipids but also by increasing levels of beneficial 
metabolites.
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